Free Newsletter
Aveo designs better mice to trap better therapies
Cambridge, MA-based Aveo Pharmaceuticals says it's developed a better mouse model for cancer tumors that will give it a big advantage in the race to develop new cancer therapies. But Aveo says this is one advance that they intend to keep in-house for use solely with their own discovery programs.
The work involves taking mouse stem cells and providing genetic directions so that they develop specific cancer types. The tumors begin to develop with the introduction of an agent in their water that activates a genetic switch. The cells are programmed to produce an enzyme that is the same that makes fireflies glow. That enables Aveo scientists to monitor the growth or shrinkage of the tumors without having to cut the animals open.
- see Aveo's diagram on the new mouse model
- read the article from The Boston Globe
Related Articles:
AVEO gains $53M in financing. Report
AVEO buys anti-cancer compound from Kirin. Report
Mouse model for embryonic stem cell research. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: